BiotechTube
Magnus Medical

Magnus Medical

San Francisco, United States· Est.
magnusmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Magnus Medical is a private, commercial-stage medical device company that has brought a novel, accelerated form of Transcranial Magnetic Stimulation (TMS) to market. Its SAINT Therapy combines personalized fMRI brain mapping with a proprietary targeting algorithm to deliver high-dose TMS over five days, achieving rapid remission for patients with treatment-resistant depression. The company holds FDA 510(k) clearance and Breakthrough Device Designation, positioning it to disrupt the standard of care for depression treatment.

Major Depressive DisorderPsychiatry

Technology Platform

Personalized fMRI-guided, accelerated Transcranial Magnetic Stimulation (TMS) platform. Uses individual brain scans and a proprietary algorithm to determine precise stimulation targets, followed by a high-dose, 5-day treatment regimen.

Funding History

1
Total raised:$25M
Seed$25M

Opportunities

The large, underserved population with treatment-resistant depression represents a multi-billion dollar market.
SAINT's rapid 5-day protocol addresses key limitations of current therapies (slow onset, lengthy duration), offering a strong value proposition for patients, clinicians, and payers seeking efficient, high-efficacy treatments.
The platform technology is also potentially expandable to other neuropsychiatric disorders.

Risk Factors

Key risks include securing widespread insurance reimbursement for the novel protocol and fMRI component, driving adoption in a conservative medical community, and competing against established TMS systems and new pharmacological therapies.
Long-term durability data in real-world settings is also still being accumulated.

Competitive Landscape

Competitors include established TMS device companies (e.g., Neuronetics, BrainsWay) offering conventional 6-week protocols, pharmaceutical companies with antidepressants and rapid-acting agents like Spravato (esketamine), and emerging therapies in psychedelics. SAINT's differentiation lies in its personalized targeting, accelerated schedule, and high remission rates from published trials.

More companies in Neuroscience & CNS →More companies in United States →